Injection drug users (IDUs) can achieve excellent results through Sovaldi (sofosbuvir)-based hepatitis C virus (HCV) treatment, aidsmap reports.
Researchers studied the hep C treatment outcomes of 456 IDUs with genotypes 1 through 4 of the virus who began HCV treatment between July 2015 and April 2016.
Eighty-nine percent of the cohort were also living with HIV, and 97 percent of that group were on antiretroviral (ARV) treatment for HIV. Fourteen percent of the overall group had previously been treated for HCV with interferon-based therapy. Eight percent were receiving opioid substitution therapy.
The majority of the cohort was treated for 12 weeks with Sovaldi plus interferon and ribavirin.
Ninety-three percent of the cohort achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure).
To read the aidsmap article, click here.
To read the conference abstract, click here.